| The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the … L Emmett, J Buteau, N Papa, D Moon, J Thompson, MJ Roberts, K Rasiah, ... European urology 80 (6), 682-689, 2021 | 249 | 2021 |
| PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu] Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP … JP Buteau, AJ Martin, L Emmett, A Iravani, S Sandhu, AM Joshua, ... The Lancet Oncology 23 (11), 1389-1397, 2022 | 109 | 2022 |
| The PRIMARY score: using intraprostatic 68Ga-PSMA PET/CT patterns to optimize prostate cancer diagnosis L Emmett, N Papa, J Buteau, B Ho, V Liu, M Roberts, J Thompson, ... Journal of Nuclear Medicine 63 (11), 1644-1650, 2022 | 73 | 2022 |
| The value of PET in mild cognitive impairment, typical and atypical/unclear dementias: a retrospective memory clinic study R Laforce Jr, JP Buteau, N Paquet, L Verret, M Houde, RW Bouchard American Journal of Alzheimer's Disease & Other Dementias® 25 (4), 324-332, 2010 | 66 | 2010 |
| Cognitive impairment in ARCA-1, a newly discovered pure cerebellar ataxia syndrome R Laforce, JP Buteau, JP Bouchard, GA Rouleau, RW Bouchard, N Dupré The Cerebellum 9, 443-453, 2010 | 34 | 2010 |
| PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic … JP Buteau, AJ Martin, L Emmett, A Iravani, SK Sandhu, AM Joshua, ... Journal of Clinical Oncology 40 (6_suppl), 10-10, 2022 | 29 | 2022 |
| Radiation dosimetry in 177Lu-PSMA-617 therapy P Jackson, M Hofman, L McIntosh, JP Buteau, AR Kumar Seminars in Nuclear Medicine 52 (2), 243-254, 2022 | 26 | 2022 |
| Neuroimaging in dementias S Mahalingam, MK Chen Seminars in Neurology 39 (02), 188-199, 2019 | 25 | 2019 |
| Role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer D Bagguley, S Ong, JP Buteau, S Koschel, N Dhiantravan, MS Hofman, ... Future Oncology 17 (17), 2225-2241, 2021 | 24 | 2021 |
| Administering [177Lu] Lu-PSMA-617 prior to radical prostatectomy in men with high-risk localised prostate cancer (LuTectomy): a single-centre, single-arm, phase 1/2 study RS Eapen, JP Buteau, P Jackson, C Mitchell, SF Oon, O Alghazo, ... European Urology 85 (3), 217-226, 2024 | 20 | 2024 |
| Prostate‐specific membrane antigen theranostics in advanced prostate cancer: an evolving option N Mayor, NJ Sathianathen, J Buteau, S Koschel, M Antón Juanilla, ... BJU international 126 (5), 525-535, 2020 | 20 | 2020 |
| Overall survival with [177Lu] Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase … MS Hofman, L Emmett, S Sandhu, A Iravani, JP Buteau, AM Joshua, ... The Lancet Oncology 25 (1), 99-107, 2024 | 19 | 2024 |
| AlphaBet: combination of radium-223 and [177Lu] Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol) L Kostos, JP Buteau, T Yeung, JD Iulio, J Xie, A Cardin, KY Chin, ... Frontiers in medicine 9, 1059122, 2022 | 18 | 2022 |
| High prostate‐specific membrane antigen (PSMA) positron emission tomography (PET) maximum standardized uptake value in men with PI‐RADS score 4 or 5 confers a high probability … G Ptasznik, N Papa, BD Kelly, J Thompson, P Stricker, MJ Roberts, ... Bju International 130 (Suppl 3), 5, 2022 | 12 | 2022 |
| VIOLET: A phase I/II trial evaluation of radioligand treatment in men with metastatic castration-resistant prostate cancer with [161Tb]Tb-PSMA-I&T. JP Buteau, LK Kostos, R Alipour, P Jackson, L McIntosh, B Emmerson, ... Journal of Clinical Oncology 41 (6_suppl), TPS281-TPS281, 2023 | 9 | 2023 |
| Evaluation of a semi-automated whole body PET segmentation method applied to Diffuse Large B Cell Lymphoma R Niman, JP Buteau, A Kruzer, A Nelson Journal of Nuclear Medicine 59 (supplement 1), 592-592, 2018 | 9 | 2018 |
| Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer L Kostos, JP Buteau, MS Hofman, AA Azad Therapeutic Advances in Medical Oncology 15, 17588359231179309, 2023 | 8 | 2023 |
| TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. PSMA and FDG-PET as predictive and prognostic biomarkers in patients … JP Buteau, AJ Martin, L Emmett, A Iravani, S Sandhu, AM Joshua, ... Lancet Oncol 23 (11), 1389-1397, 2022 | 8 | 2022 |
| 68Ga-DOTATATE uptake in ischemic stroke É Vallée, N Paquet, JP Buteau, É Turcotte Clinical Nuclear Medicine 43 (1), 46-47, 2018 | 8 | 2018 |
| 18F-FDG PET/CT uptake of a nonbacterial thrombotic endocarditis JP Buteau, J Morais, KV Keu Journal of Nuclear Cardiology 23, 1501-1503, 2016 | 7 | 2016 |
